Predicting and assessing the response of borderline resectable pancreatic cancer to neoadjuvant chemotherapy: Methodological approaches
Borderline resectable pancreatic cancer (BRPC) represents a complex clinical entity characterized by anatomical, biological, and conditional heterogeneity. Accurate assessments of resectability and the response to neoadjuvant chemotherapy (NAC) are crucial for determining surgical eligibility and improving overall...